After a year off, Gift of Life and Breath 5K makes a strong return.
October 7, 2014 · Comments Off
Lung cancer is the leading cause of cancer-related deaths in the United States for men...
NEJM: Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
September 30, 2014 · 1 comment
The New England Journal of Medicine reports positive results of a phase 1 clinical trial of the drug crizotinib against the subset of lung cancer marked by rearrangement of the gene ROS1.
Guest Blog: GOLAB aims to beat lung cancer
September 2, 2014 · Comments Off
By: Thelissa Zollinger On April 29, 2004, my life was to change forever. Gary, my...
University of Colorado’s Online Screening for Rare Lung Cancer Subtypes Opens Door to New Kind of Clinical Trial
August 21, 2014 · Comments Off
CU Cancer Center clinical trial tests the drug ponatinib against lung cancer with mutation in the gene FGFR1. Online questionnaire and free lung cancer tissue testing at CU determines eligibility.
Cancer Center Lends a Hand in Alaskan’s Lung Cancer Battle
July 24, 2014 · Comments Off
A year and a half ago, she considered herself one lucky lady. It was Dec....
Epic Experience gives cancer survivors memories that last a life time
July 24, 2014 · Comments Off
At a small mountain ranch in Sweetwater, Colo., University of Colorado Cancer Center patients are...
Paul A. Bunn, Jr, MD earns 2014 “Giants of Cancer Care” award
June 11, 2014 · Comments Off
AURORA, Colo. – University of Colorado Cancer Center investigator Paul A. Bunn, Jr, MD, has...
Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
June 2, 2014 · Comments Off
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
One Step Closer to a Breath Test for Lung Cancer
May 31, 2014 · Comments Off
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
NTRK1: a new oncogene and target in lung cancer
May 31, 2014
Mutations Need Help From Aging Tissue to Cause Leukemia
December 18, 2014 · No comments
Is a Treatment For Your Cancer Sitting on a Dusty Shelf?
December 15, 2014 · No comments
ALK amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer clinical trials cancer grants cancer research colorado Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
The Fall 2014 C3 magazine is here! Be sure to check it out!! issuu.com/coloradocancer…
“I absolutely believe there is hope on the horizon for pancreatic cancer,” coloradocancerblogs.org/hitting-pancre…